Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 7/20 | 0.97 |
| ▸ | CHRM2 known ✓ | P08172 | 3/20 | 0.54 |
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.54 |
| ▸ | CHRM1 known ✓ | P11229 | 3/20 | 0.54 |
| ▸ | ADRA2B known ✓ | P18089 | 3/20 | 0.54 |
| ▸ | ADRA2C known ✓ | P18825 | 3/20 | 0.54 |
| ▸ | CHRM3 known ✓ | P20309 | 3/20 | 0.54 |
| ▸ | DRD1 known ✓ | P21728 | 3/20 | 0.54 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.54 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 0.54 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.54 |
| ▸ | HRH1 known ✓ | P35367 | 3/20 | 0.54 |
| ▸ | HTR2B known ✓ | P41595 | 3/20 | 0.54 |
| ▸ | KCNH2 known ✓ | Q12809 | 3/20 | 0.54 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.54 |
| ▸ | OPRM1 known ✓ | P35372 | 2/20 | 0.54 |
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.54 |
| ▸ | CHRM4 known ✓ | P08173 | 2/20 | 0.54 |
| ▸ | CHRM5 known ✓ | P08912 | 2/20 | 0.54 |
| ▸ | ADRA1D known ✓ | P25100 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1943859 | 1.00 | DRD2 (0.97) | DRD2CHRM2ADRA2ACHRM1ADRA2B | |
| SCHEMBL29368614 | 0.99 | DRD2 (1.00) | DRD2CHRM2ADRA2ACHRM1ADRA2B | |
| SCHEMBL8311 | 0.99 | DRD2 (1.00) | DRD2CHRM2ADRA2ACHRM1ADRA2B | |
| Sulfuric Acid SCHEMBL4143302 | 0.92 | DRD2 (0.87) | DRD2CHRM2ADRA2ACHRM1ADRA2B | |
| Phosphoric Acid SCHEMBL4151583 | 0.91 | DRD2 (0.85) | DRD2CHRM2ADRA2ACHRM1ADRA2B | |
| SCHEMBL4146089 | 0.90 | DRD2 (0.83) | DRD2CHRM2ADRA2ACHRM1ADRA2B | |
| SCHEMBL8022151 | 0.88 | DRD2 (0.80) | DRD2CHRM2ADRA2ACHRM1ADRA2B | |
| SCHEMBL11555179 | 0.85 | DRD2 (0.76) | DRD2CHRM2ADRA2ACHRM1ADRA2B | |
| SCHEMBL2159879 | 0.84 | DRD2 (0.74) | DRD2CHRM2ADRA2ACHRM1ADRA2B | |
| SCHEMBL12395990 | 0.84 | DRD2 (0.74) | DRD2CHRM2ADRA2ACHRM1ADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010001407-A2 | SYNTHESIS OF 11-(4-[2-(2-HYDROXYETHOXY)ETHYL]- PIPERAZINYL)DIBENZO[B,F][1,4]THIAZEPINE AND ITS FUMARATE SALT | INOGENT LABORATORIES PRIVATE LIMITED (IN) | 2010-01-07 | — | — | WO | claimed |
| US-20240342189-A1 | ORAL QUETIAPINE SUSPENSION FORMULATIONS WITH EXTENDED SHELF LIFE AND ENHANCED BIOAVAILABILITY | TLC THERAPEUTICS LLC (US) | 2024-10-17 | — | — | US | disclosed |
| US-12023340-B2 | Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability | TLC THERAPEUTICS, LLC | 2024-07-02 | — | — | US | disclosed |
| US-10940155-B2 | Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability | TLC THERAPEUTICS, LLC (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200179399-A1 | ORAL QUETIAPINE SUSPENSION FORMULATIONS WITH EXTENDED SHELF LIFE AND ENHANCED BIOAVAILABILITY | TLC THERAPEUTICS LLC (US) | 2020-06-11 | — | — | US | disclosed |
| US-10561669-B2 | Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability | TLC THERAPEUTICS, LLC (US) | 2020-02-18 | — | — | US | disclosed |
| US-20180360844-A1 | ORAL QUETIAPINE SUSPENSION FORMULATIONS WITH EXTENDED SHELF LIFE AND ENHANCED BIOAVAILABILITY | ROSEMONT PHARMACEUTICALS LIMITED (GB) | 2018-12-20 | — | — | US | disclosed |
| US-9993486-B1 | Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability | TLC THERAPEUTICS, LLC (US) | 2018-06-12 | — | — | US | disclosed |
| EP-2245021-B1 | A PROCESS FOR THE PREPARATION OF QUETIAPINE | FERMION OY (FI) | 2012-09-12 | — | — | EP | disclosed |
| US-20120071649-A1 | PROCESS FOR THE PREPARATION OF QUETIAPINE FUMARATE | RANBAXY LABORATORIES LIMITED (IN) | 2012-03-22 | — | — | US | disclosed |
| US-20060252743-A1 | Method of treating sleep disorders | ASTRAZENECA AB (SE) | 2006-11-09 | — | — | US | disclosed |
| US-20060229292-A1 | Method of treating childhood disorders | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | US | disclosed |
| US-20060217366-A1 | Method of treating schizophrenia and other disorders | ASTRAZENECA AB (SE) | 2006-09-28 | — | — | US | disclosed |
| US-20060217365-A1 | Method of treating mood disorders | ASTRAZENECA AB (SE) | 2006-09-28 | — | — | US | disclosed |
| WO-2006073360-A1 | NEW USE OF 11-PIPERAZIN-1-YLDIBENZO [b,f] [1,4] THIAZEPINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND TO ORAL PHARMACEUTICAL COMPOSITIONS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
| EP-0282236-B1 | PROCESS FOR THE PREPARATION OF A THIAZEPINE COMPOUND | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-12-11 | — | — | EP | disclosed |
| EP-0240228-B1 | THIAZEPINE COMPOUNDS | ICI AMERICAS INC. (US) | 1990-11-07 | — | — | EP | disclosed |
| US-4879288-A | Novel dibenzothiazepine antipsychotic | ICI AMERICAS INC. (US) | 1989-11-07 | — | — | US | disclosed |
| EP-0282236-A1 | Process for the preparation of a thiazepine compound | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-09-14 | — | — | EP | disclosed |
| EP-0240228-A1 | Thiazepine compounds | ICI AMERICAS INC. (US) | 1987-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252743-A1 | Method of treating sleep disorders | SMPD4, HCRTR2, MTNR1B | DRD2 281/4885CHRM2 18/4885ADRA2A 76/4885 |
| US-20120071649-A1 | PROCESS FOR THE PREPARATION OF QUETIAPINE FUMARATE | FH, CYP3A5, SDHA | DRD2 486/4885CHRM2 1687/4885ADRA2A 1307/4885 |
| US-20060217365-A1 | Method of treating mood disorders | MC2R, SLC6A11, HSD11B2 | DRD2 238/4885CHRM2 259/4885ADRA2A 201/4885 |
| US-20060217366-A1 | Method of treating schizophrenia and other disorders | SLC6A3, SLC6A1, SLC6A11 | DRD2 17/4885CHRM2 152/4885ADRA2A 291/4885 |
| US-20060229292-A1 | Method of treating childhood disorders | SLC6A3, SLC6A1, SLC18A2 | DRD2 129/4885CHRM2 2396/4885ADRA2A 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.